SV

Street Verdict

Analyst Scorecard

NIFTYMIDSMALLHEALTHCARE · NSE

Nifty MidSmall Healthcare

Index · View only — not on the trading terminal

₹54,291.6

+0.71% (+₹381.35)

Prev. close

₹53,910.25

Volume

2,46,86,122

As of

20 Nov 2026

Price history

₹54,291.6+₹2,059.15 (+3.94%) · 3M
18 Aug 2026 → 20 Nov 2026
48,00049,00050,00051,00052,00053,00054,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range — no analyst has covered this yet.

Explore by date range →

Analyst opinions

No analyst calls on Nifty MidSmall Healthcare yet.

Composition

30 stocks

Member stocks, ranked by today's change — biggest gainers first, biggest losers last.

StockPrice · Day

Index levels are informational only, not investment advice.

NATCOPHARM

NATCO Pharma's (NSE:NATCOPHARM) Problems Go Beyond Weak Profit

Simply Wall St · 2 days ago

PPLPHARMA

Piramal Pharma Share Price Today Down 2.44%: What It Shows

Piramal Pharma shares fell to Rs 189.70, down 2.44% from the prior close of Rs 194.45, after opening near Rs 194.70 and reaching an intraday high of Rs 199.50. The decline occurs amid a large‑cap company reporting a P/B of 3.23x, negative ROE of 4.04% and EPS of Rs ‑2.36, figures that lag industry benchmarks.

2 days ago·Read at Univest
MANKIND

How JSW Steel, Dr Reddy’s, Mankind Pharma are fine-tuning AI investments

Mankind Pharma’s global CFO, Ashutosh Dhawan, highlighted the company’s AI strategy at the ETCFO Annual Conclave, stressing the need to balance immediate productivity gains with long‑term capability building. Dhawan noted that Mankind Pharma is prioritising AI projects that deliver measurable operational efficiencies while also investing in foundational data and compliance systems that may not show instant ROI. This dual approach aims to strengthen future competitiveness without compromising current financial discipline.

ACUTAAS

Acutaas Chemicals falls 3.80% in Friday's session

Global Banking & Finance Review · 2 days ago

NEULANDLAB

Neuland Laboratories falls 2.85% in Friday's session

Global Banking & Finance Review · 2 days ago

MEDANTA

UAE ranks joint first globally in personal safety, scores 96% in Gallup Global Safety Report

Gulf News · 2 days ago

KIMS

Krishna Institute of Medical Sciences (NSE: KIMS) Q2 FY27 Results: Revenue Growth and Margin Trends

Kalkine India · 2 days ago

FORTIS

Max Healthcare, Apollo Hospitals, other healthcare stocks surge over 5% despite volatile market; what’s behind the surge?

Upstox · 3 days ago

NH

BSE Hospitals index soars 3%; Apollo, Max, Narayana Hrudayalaya surge 5%

Business Standard · 3 days ago

FORTIS

Max Healthcare stock highlights H1 growth and bed expansion

ad-hoc-news.de · 3 days ago

GLAND

Gland Pharma Holders Are Up 93% And Here Is What They Saw

Gland Pharma’s shares have risen about 93% year‑to‑date, reaching roughly ₹3,293 from ₹1,715 at the start of 2026. The rally follows a U.S. FDA approval for a methylprednisolone injectable, which helped lift quarterly revenue to ₹18.34 billion and improve net margin to 15.9%, prompting optimistic fair‑value estimates despite some analysts warning of capacity‑utilisation risks.

ALKEM

Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

Upstox · 3 days ago

MEDANTA

As Global Health Aid Dries Up, Non-Profit Drug Development Faces New Challenges

Global Health Limited faces a shrinking funding environment as donor governments cut global health budgets, with the Gates Foundation reducing PDP grants by nearly a quarter in 2024 and the UK’s support rising only modestly. This financial squeeze threatens the development pipeline of neglected‑disease medicines, as 12 product development partnerships report nearly 300 candidates in various trial stages. The uncertainty may force a “natural selection” of the most viable partnerships, potentially curtailing progress against malaria, tuberculosis and other tropical diseases.

PPLPHARMA

Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio

BusinessLine · 4 days ago

ANTHEM

Anthem Biosciences IPO GMP Today with Trend

IPO Watch · 4 days ago

ANTHEM

Anthem Biosciences IPO Date, Price Band, Issue Size

IPO Watch · 4 days ago

NATCOPHARM

Natco Pharma Q2 FY27 revenue falls 30% as profit drops 61%

Multibagg AI · 4 days ago

SAILIFE

Sai Life Sciences rises 2.11% in Wednesday's session

Global Banking & Finance Review · 4 days ago

GRANULES

Granules India falls 2.76% in Wednesday's session

Granules India’s shares declined 2.76% during Wednesday’s trading session. The drop contributed to a broader weakening in the Indian pharmaceutical sector, indicating investor sensitivity to recent earnings reports and market sentiment.

SAILIFE

Aragen Life Sciences Plans ₹1,500 Crore Expansion Investment

Voice of Healthcare · 4 days ago